MarketScreener Homepage > Equities > Nyse > Merck & Co., Inc. MRK

Report

Delayed Nyse - 10/23 04:10:00 pm
79.83	USD		+0.78%

10/23

MERCK : Why Merck Is Playing Catch-Up in the Coronavirus -2-

10/23

Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

10/23

MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

News

All News

Official Publications

Sector news

MarketScreener Strategies

Analyst Recommendations

All news about MERCK & CO., INC.

10/23	MERCK : Why Merck Is Playing Catch-Up in the Coronavirus -2-	DJ
10/23	Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase	DJ
10/23	MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..	AQ
10/23	MERCK : PHIL, MERCK Partner to Reach Girls With HPV Vaccine	AQ
10/22	MERCK & CO., INC. : quaterly earnings release
10/22	MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..	BU
10/22	Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue	DJ
10/21	SANOFI : Merck and Sanofi to Present Three New Studies Highlighting Combination ..	AQ
10/21	MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..	AQ
10/21	MERCK : to Present New Data from its Extensive Infectious Diseases and Vaccines ..	BU
10/20	MERCK : and Sanofi to Present Three New Studies Highlighting Combination Pediatr..	PU
10/20	MERCK : Reports More Positive Phase 3 Study Results for V114 Vaccine	DJ
10/20	MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..	BU
10/16	MERCK : Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combi..	BU
10/16	MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients ..	AQ
10/15	MERCK : Issues 2019, 2020 Corporate Responsibility Report	AQ
10/15	MERCK : Gets FDA Expanded Approval for Keytruda in Classical Hodgkin Lymphoma	DJ
10/15	MERCK : Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment..	AQ
10/15	MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) i..	BU
10/14	MERCK : Announces Plans to Construct New Facility in the United States to Expand..	PU
10/14	MERCK : Issues 2019/2020 Corporate Responsibility Report	BU
10/09	MERCK : Intec Pharma Announces New Research Collaboration Agreement with MSD	AQ
10/09	MODERNA : Announces Updates on Respiratory Syncytial Virus Vaccine Program	AQ
10/08	MERCK : Moderna Regains Rights to RSV Vaccine From Merck	DJ
10/08	MERCK : Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Comb..	BU
10/05	MERCK : Announces Retirement of Dr. Roger M. Perlmutter, Dr. Dean Y. Li Appointe..	AQ
10/02	MERCK : R&D Chief to Retire -- Update	DJ
10/02	MERCK : to Present New Data from the Company's Diverse HIV Portfolio and Pipelin..	AQ
10/02	MERCK : to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October..	AQ
10/02	MERCK : Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointe..	BU
10/01	MERCK : to Present New Data from the Company's Diverse HIV Portfolio and Pipelin..	BU
10/01	MERCK : to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October..	BU
09/30	CELYAD : Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 wi..	AQ
09/29	MERCK : Animal Health Supports Rabies Elimination by 2030 on World Rabies Day	AQ
09/29	MERCK : Enters into Voluntary Licensing Agreements for Doravirine to Expand Pati..	PU
09/28	MERCK : Animal Health Supports Rabies Elimination by 2030 on World Rabies Day	BU
09/24	MERCK : 4D pharma plc - Directorate Change	AQ
09/24	MERCK : NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada	AQ
09/23	MERCK : 4D pharma makes strategic appointment of independent Non-Executive Direc..	AQ
09/22	MERCK : Merk Oncology Overview ESMO 2020 Presentation	PU
09/22	ALX ONCOLOGY : Merck to Collaborate on Head and Neck Cancer Treatment Trials	DJ
09/21	MERCK : Keytruda in Combination Reduced Risk of Death in Certain Esophageal Canc..	DJ
09/21	MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27%..	BU
09/21	ASTRAZENECA : Merck Get CHMP Positive Opinions for Expanded Lynparza Use	DJ
09/21	MERCK : And eisai present first-time data from two studies evaluating keytruda p..	AQ
09/21	MERCK : First-Line Treatment With Merck's KEYTRUDA® (pembrolizumab) Doubled Five..	BU
09/21	MERCK : LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatmen..	BU
09/21	MERCK : LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Lin..	BU
09/20	MERCK : LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone fo..	BU
09/20	MERCK : Presents Promising New Data for Three Investigational Medicines From Div..	BU
09/20	MERCK : and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® ..	BU
09/19	MERCK : KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Deat..	BU
09/18	AstraZeneca, Merck Say Lynparza Demonstrates Long-Term Progression-Free Survi..	DJ
09/18	MERCK : LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over F..	BU
09/17	MERCK : Vaccinex Shares Climb 18% on Keytruda Collaboration With Merck	DJ
09/17	MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020	AQ
09/16	MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..	AQ
09/16	MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020	BU
09/15	SEATTLE GENETICS : and Merck Announce Two Strategic Oncology Collaborations	AQ
09/15	MERCK : BRENZYS® (etanercept injection) now indicated for the Treatment of Plaqu..	AQ
09/15	MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..	BU
09/15	MERCK : Makes $1 Billion Deal	DJ
09/15	MERCK : HHS Can't Force Disclosure Of Drug Prices In Ads With "Blunderbuss" Rule	AQ
09/14	EISAI : To present abstracts on oncology products and pipeline at esmo virtual c..	AQ
09/14	MERCK : to Invest $1 Billion in Seattle Genetics, Collaborate on Breast-Cancer T..	DJ
09/14	MERCK : Seattle Genetics and Merck Announce Two Strategic Oncology Collaboration..	BU
09/14	MERCK & CO., INC. : Ex-dividend day for	FA
09/11	Merck starts recruitment for COVID-19 vaccine trial	RE
09/11	Merck Covid-19 Vaccine Begins Human Testing--Update	DJ
09/10	MERCK : Announces Positive Topline Results from Two Phase 3 Adult Studies Evalua..	AQ
09/10	MERCK : Intensity Therapeutics Doses First Patients with Combination of INT230-6..	AQ
09/10	MERCK : to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare C..	BU
09/09	MERCK : Gefapixant Significantly Decreased Cough Frequency Compared to Placebo a..	AQ
09/09	AstraZeneca - Biopharma Leaders Unite to Stand With Science	AQ
09/09	Biopharma Leaders Unite To Stand With Science	AQ

1 2 3 4 5 6 7 8 9 10 Next

Analysis

Merck to move COVID-19 treatment into large trials, sees sales recovering this year